A landmark study published in the New England Journal of Medicine today heralds a new era in stroke treatment across the globe
A landmark study published in the New England Journal of Medicine today heralds a new era in stroke treatment across the globe.
EXTEND-IA*, an Australian and New Zealand randomised clinical research study, led by The Royal Melbourne Hospital (RMH), looked at the effectiveness of a new treatment for stroke.
The study involved adding a minimally invasive clot removal procedure called stent thrombectomy to standard clot-dissolving therapy, known as tissue plasminogen activator (tPA).
Royal Melbourne Hospital Neurologist and co-principal investigator, Dr Bruce Campbell, said the study showed a dramatic improvement in restoring blood flow back to the brain, which is critical in the recovery of stroke.
"In 89 percent of patients blood flow to the brain was restored when the clot removal therapy was used compared with 34 percent of patients who had standard clot-dissolving therapy alone," Dr Campbell said.
"The addition of stent thrombectomy to standard clot-dissolving treatment led to 71 percent of patients returning to independent living, compared with 40 percent in the standard treatment group.
"This is an extremely impressive outcome given these patients had the most severe forms of stroke and dramatically reduces the burden of disability."
The most common form of stroke is an ischemic stroke, caused by a clot blocking a blood vessel that supplies the brain. Stroke is the leading cause of disability in adults and the number two cause of death worldwide.
The EXTEND-IA trial builds on an earlier Dutch study, MR-CLEAN, which was presented at the 9th World Stroke Congress, Istanbul 25 October 2014 and also published in the New England Journal of Medicine.
Go here to read the rest:
New study 'game-changer' for stroke treatment worldwide